Bladder Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Bladder Cancer Marketed and Pipeline Drugs Market Report Overview
There are 13 marketed innovator therapies for bladder cancer, with an almost equal number of small molecules and biologics. The Bacillus Calmette-Guerin (BCG) vaccine is considered a gold-standard therapy in high-risk NMIBC (non-muscle-invasive bladder cancer) patients.
The bladder cancer marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in bladder cancer therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing, and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for bladder cancer.
Leading Marketed Drugs for Bladder Cancer
The key marketed drugs in the bladder cancer market are atezolizumab, avelumab, Bacillus Calmette-Guerin [strain Tice] vaccine, and disitamab vedotin among others. The marketed drug space for bladder cancer is mostly made up of checkpoint inhibitors targeting proteins like PD-1 or PD-L1.
Bladder Cancer Marketed Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for bladder cancer marketed drugs are enzyme inhibitor, receptor agonist, receptor antagonist, cytotoxic, and receptor inhibitor among others. Enzyme inhibitor was the most common mechanism of action for bladder cancer marketed drugs.
Bladder Cancer Marketed Drugs Analysis, by Mechanism of Action
For more MoA insights into the bladder cancer marketed drugs, download a free report sample
Bladder Cancer Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for bladder cancer marketed drugs are injection, oral, suppository, and inhalational. The majority of marketed drugs for bladder cancer are injection therapies.
Bladder Cancer Marketed Drugs Analysis, by Routes of Administration
For more RoA insights into the bladder cancer marketed drugs, download a free report sample
Bladder Cancer Marketed Drugs Segmentation by Molecule Type
The key molecule types in the market are small molecule and biologics. The marketed drugs space for bladder cancer is made up of almost equal numbers of small molecules and biologics.
Bladder Cancer Marketed Drugs Analysis, by Molecule Type
For more molecule type insights into the bladder cancer marketed drugs, download a free report sample
Leading Pipeline Drugs for Bladder Cancer
Some of the leading pipeline drugs for bladder cancer are enfortumab vedotin, nadofaragene firadenovec, nivolumab, nogapendekin alfa, apaziquone, and atezolizumab among others.
Bladder Cancer Pipeline Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for bladder cancer pipeline drugs are cytotoxic, enzyme inhibitor, protein & peptide inhibitor, receptor agonist, receptor antagonist, and receptor inhibitor among others. Cytotoxic lead the MoA segment in the bladder cancer pipeline drugs market.
Bladder Cancer Pipeline Drugs Analysis, by Mechanisms of Action
For more MoA insights into the bladder cancer pipeline drugs market, download a free report sample
Bladder Cancer Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for bladder cancer pipeline drugs are injection, oral, topical, suppository, and inhalational. The majority of pipeline drugs for bladder cancer are injection therapies.
Bladder Cancer Pipeline Drugs Analysis, by Routes of Administration
For more RoA insights for bladder cancer pipeline drugs market, download a free report sample
Bladder Cancer Pipeline Drugs Segmentation by Molecule Type
The bladder cancer pipeline drugs comprise mostly biologics, oligonucleotide, and small molecule. Most drugs in development for the treatment of bladder cancer are biologics.
Bladder Cancer Pipeline Drugs Analysis, by Molecule Types
For more molecule type insights into the bladder cancer pipeline drugs, download a free report sample
Bladder Cancer Marketed and Pipeline Drugs Market - Top Clinical Trial Sponsors
Some of the top clinical trial sponsors in the bladder cancer marketed and pipeline drugs market are National Cancer Institute US, Incyte, Bristol Myers Squibb, Pfizer Inc, and Mayo Clinic among others.
Bladder Cancer Marketed Drugs Market Overview
Key Mechanisms of Action | Enzyme Inhibitor, Receptor Agonist, Receptor Antagonist, Cytotoxic, and Receptor Inhibitor |
Key Routes of Administration | Injection, Oral, Suppository, and Inhalational |
Key Molecule Types | Small Molecule and Biologics |
Bladder Cancer Pipeline Drugs Market Overview
Key Mechanisms of Action | Cytotoxic, Enzyme Inhibitor, Protein & Peptide Inhibitor, Receptor Agonist, Receptor Antagonist, and Receptor Inhibitor |
Key Routes of Administration | Injection, Oral, Topical, Suppository, and Inhalational |
Key Molecule Types | Biologics, Oligonucleotide, and Small Molecule |
Top Clinical Trial Sponsors
|
National Cancer Institute US, Incyte, Bristol Myers Squibb, Pfizer Inc, and Mayo Clinic |
Scope
GlobalData’s bladder cancer Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combine data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the bladder cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for bladder cancer marketed drugs?
Some of the key mechanisms of action for bladder cancer marketed drugs are enzyme inhibitor, receptor agonist, receptor antagonist, cytotoxic, and receptor inhibitor.
-
What are the key routes of administration for bladder cancer marketed drugs?
The key routes of administration for bladder cancer marketed drugs are injection, oral, suppository, and inhalational.
-
What are the key molecule types for bladder cancer marketed drugs?
The key molecule types for bladder cancer marketed drugs are small molecule and biologics.
-
What are the key mechanisms of action for bladder cancer pipeline drugs?
Some of the key mechanisms of action for bladder cancer pipeline drugs are cytotoxic, enzyme inhibitor, protein & peptide inhibitor, receptor agonist, receptor antagonist, and receptor inhibitor.
-
What are the key routes of administration for bladder cancer pipeline drugs?
The key routes of administration for bladder cancer pipeline drugs are injection, oral, topical, suppository, and inhalational.
-
What are the key molecule types for bladder cancer pipeline drugs?
The key molecule types in bladder cancer pipeline drugs are biologics, oligonucleotide, and small molecule.
-
Who are the top clinical trial sponsors for the bladder cancer marketed and pipeline drugs market?
Some of the top clinical trial sponsors for the bladder cancer marketed and pipeline drugs market are National Cancer Institute US, Incyte, Bristol Myers Squibb, Pfizer Inc, and Mayo Clinic.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.